Frazier Life Sciences Builds 15.3% Stake in Attovia Therapeutics After IPO, Adding $3.3M in Open Market Buys

summarizeSummary

Frazier Life Sciences reports a 15.3% stake in Attovia Therapeutics, including $3.3 million in post-IPO open market purchases, reinforcing institutional support as the stock hovers near lows.

check_boxKey Events · Ownership and Investor Activity · ATTO

• Frazier Group Holds 15.3% Stake

  Collectively, Frazier Life Sciences entities own 6,968,703 shares, or 15.3% of the outstanding total. FLS XI holds 6,154,213 shares (13.5%), while FLSPF holds 760,327 shares (1.7%).

• $3.3M in Post-IPO Open Market Buys

  On August 5–7, FLSPF and FLS XII purchased $3,306,368.83 worth of shares at prices ranging from $19.37 to $22.00, adding to the $10 million IPO purchase by FLS XI at $17.00.

• Pre-IPO Private Placement Conversion

  FLS XI's stake includes 5,565,980 shares from the conversion of preferred stock purchased in private transactions for approximately $59.98 million, plus 588,235 shares bought in the IPO.

• 180-Day Lock-Up on FLS XI Shares

  A lock-up agreement prevents FLS XI from disposing of or hedging its shares for 180 days post-IPO, limiting near-term selling pressure.

auto_awesomeAnalysis · ATTO · Life Sciences

A prominent life sciences venture capital group, Frazier Life Sciences, has disclosed a combined 15.3% stake in Attovia Therapeutics following the company's recent IPO. The 13D reveals that Frazier entities purchased an additional $3.3 million worth of shares in the open market on August 5–7 at prices between $19.37 and $22.00, on top of the previously reported $10 million IPO purchase by FLS XI. With total holdings of nearly 7 million shares, including pre-IPO private placements, the group signals strong institutional conviction in Attovia's prospects—especially as the stock trades near its 52-week low. The filing also notes that FLS XI is subject to a 180-day lock-up agreement, limiting near-term selling pressure.